Archive for July 2021
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions.
Willmann S., Coboeken K., Zhang Y, Mayer H., Ince I, Mesic E., Thelen K., Kubitza D., Lensing A.W.A., Yang H., Zhu P., Mück W., Drenth H., Lippert J. Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions. CPT Pharmacometrics Syst Pharmacol. 2021 Jul 22. doi: 10.1002/psp4.12688 . [Link to publication]
Read MoreSuccessful prediction of continuous glucose dynamics and HbA1c response
Bosch R. Successful prediction of continuous glucose dynamics and HbA1c response to the GLP-1 and glucagon co-agonist cotadutide using the 4GI- HbA1c systems model The G lucose- G LP-1- G lucagon- G IP- I nsulin ( 4GI ) model. ASCPT 2021. (poster and lecture)
Read MorePopulation Dose-Response Analysis of Hemoglobin Data
Berg van der P., Post T., Ahsman M., Berg van der P., Hooijmaijers R., Snelder N., Yang S., ., Vasist L., Mahar K., Visser S. Population Dose-Response Analysis of Hemoglobin Data From Global Phase 2 and Japanese Phase 3 Studies With Daprodustat in Chronic Kidney Disease Patients With Anemia Following Once Daily (OD) or 3x…
Read MorePopulation Pharmacokinetic Analysis of Daprodustat in Healthy Volunteers (HV)
Mahar K., Post T., Ahsman M., Berg van der P., Hooijmaijers R., Snelder N., Vasist L., Visser S. Population Pharmacokinetic Analysis of Daprodustat in Healthy Volunteers (HV), Global Phase 2 and Japanese Phase 3 Studies in Chronic Kidney Disease Patients with Anemia Following Once Daily (QD) or 3x Weekly (TIW) Administration. ASCPT 2021.
Read MorePopulation Pharamcokinetic/pharmacodynamics (PKPD) Analysis of EPO during daprodustat treatment in healthy volunteers (HV) and chronic kidney disease (CKD) patients with Anemia.
Snelder N., Post T., Berg van der P., Hooijmaijers R., Ahsman M., Vasist L., Mahar K., Visser S. Population Pharamcokinetic/pharmacodynamics (PKPD) Analysis of EPO during daprodustat treatment in healthy volunteers (HV) and chronic kidney disease (CKD) patients with Anemia. ASCPT 2021.
Read MoreA population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy
DeJongh J., Ahsman M., Snelder N. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy. J. Pharmacokinet. Pharmacodyn. 7 2021 [Link to publication].
Read More